Fresenius Kabi Oncology Limited

Lahiri, Saswata

Sanghani, Sunil

Panda, Nilendu

Gupta, Nitin

Mishra, Bhuwan Bhaskar

Azim, Abul

Ojha, Vijay

Shukla, Sona Prasad

Bhuwan Bhaskar Mishra

Saswata Lahiri

Nilendu Panda

Abul Azim

Nikunj Shambhubhai Kachhadia

Nitin Kumar Gupta

Walter Cabri

Vinod Singh Tomar

Sunil Sanghani

Krishanu Ray

Poli Reddy Bhavanam

Kumber Singh

Vijay Ojha

Sonu Prasad Shukla

Sandeep Kumar

Shatrughan Sharma

Sonu Prasad

Rajesh Srivastava

Nitin Gupta

The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.

Polymorphic forms of Afatinib free base and Afatinib dimaleate

The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of &#x2267;99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.

Process for the preparation of bendamustine hydrochloride

An amorphous form of cabazitaxel is disclosed. It is preferably characterized by an X-ray powder diffraction (XRD) pattern as depicted in FIG.. It is prepared by (a) preparing a solution of cabazitaxel in a suitable solvent and mixture thereof; and (b) recovering the amorphous forms of cabazitaxel from the solution by removal of the solvent.

Amorphous form of cabazitaxel and process for its preparation

The present invention discloses a process for the preparation of 4-acetoxy-2&#x3b1;-benzoyloxy-5&#x3b2;,20-epoxy-1-hydroxy-7&#x3b2;,10&#x3b2;-dimethoxy-9-oxotax-11-en-13&#x3b1;-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I).

Process for the preparation of cabazitaxel

The present invention provides Crystalline Forms of 4-acetoxy-2&#x3b1;-benzoyloxy-5&#x3b2;-20-epoxy-1-hydroxy-7&#x3b2;,10&#x3b2;-dimethoxy-9-oxotax-11-en-13&#x3b1;-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate, i.e Cabazitaxel. The present invention also discloses methods for the preparation of Crystalline Forms of Cabazitaxel and pharmaceutical compositions thereof.

Crystalline forms of cabazitaxel and process for preparation thereof

The present invention discloses a process for the preparation of 4-acetoxy-2&#x3b1;-benzoyloxy-5&#x3b2;,20-epoxy-1-hydroxy-7&#x3b2;,10&#x3b2;-dimethoxy-9-oxotax-11-en-13&#x3b1;-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenyl-propionate Cabazitaxel (I). 

Process for the preparation cabazitaxel

Growing community of inventors

Haryana, India

Bhuwan Bhaskar Mishra